HealthCare Global Enterprises delivered a robust FY26 performance with revenue reaching INR 25,454 million, reflecting a 15% year-on-year growth. The company achieved an Adjusted EBITDA of INR 4,711 million, up 19% YoY. Furthermore, the company announced the strategic divestment of its non-core fertility business, Milann, for an enterprise valuation of INR 632 million, aimed at sharpening focus on its core oncology and allied healthcare platforms.
FY26 Financial Highlights
HealthCare Global Enterprises reported strong financial growth for the full year FY26, driven by sustained patient volume growth and steady improvements in Average Revenue Per Patient (ARPP). The company’s total revenue for the year stood at INR 25,454 million. Profitability also saw positive momentum, with Adjusted EBITDA reaching INR 4,711 million, representing an 18.5% margin. The company noted a notable expansion in ROCE to 14.0%, supported by disciplined capital allocation and improved centre maturity.
Operational Performance and Growth Drivers
The company continues to expand its footprint with 25 hospitals across 19 cities. Performance remained broad-based across all clusters: the West region led growth at ~13% YoY, followed by South at ~13% and East at ~11%. The international business also witnessed significant scaling, growing 71% YoY in FY26. A key business development during the year was the commencement of the North Bangalore facility, which introduced advanced MR-LINAC technology to the Bangalore market.
Strategic Divestment of Fertility Business
As part of its strategic shift to consolidate its position in core oncology, the company has agreed to divest 100% of its stake in BACC Healthcare Private Limited (operating under the Milann fertility brand) to Inviga Healthcare Fund I. The transaction is valued at an enterprise valuation of INR 632 million and is expected to close within Q1 FY27. This move is intended to unlock value from non-core assets and enable more efficient deployment of capital toward the expansion of oncology services.
Future Expansion Strategy
The company maintains a focus on profitable growth with a disciplined capital approach. Plans for the next 24 months include a brownfield expansion of over 200 beds across key regions including Bangalore, Cuttack, Ranchi, Vizag, and Bhavnagar. These initiatives, combined with a focus on operating leverage and asset-light adjacencies, are expected to strengthen the company’s platform for the next phase of its growth journey.
Source: BSE
